Related Experiment Video
Updated: Oct 9, 2026
Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis
Published on: October 27, 2023
Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis
1California Institute for Medical Research, San Jose, CA 95128, USA. karl.clemons@slip.net
Abstract:
The polyene partricin compound SPA-S-753 (Societa Prodotti Antibiotici, Milano, Italy) was assessed in a murine model of systemic candidosis. CD-1 mice were infected iv with Candida albicans and treated iv with SPA-S-753 or amphotericin B. All treatment regimens of SPA-S-753 or amphotericin B were equivalent and significantly prolonged survival compared with controls (P < 0.001). Amphotericin B and SPA-S-753 significantly reduced burdens of C. albicans in the spleen and kidneys. Overall, cure rates were similar, amphotericin B at 1 mg/kg cured three and SPA-S-753 at 10 mg/kg cured four mice of infection in both organs. The efficacy of SPA-S-753 is between equivalent and <10-fold as potent as amphotericin B. These results are encouraging and warrant further studies on SPA-S-753.
Insights
The novel polyene partricin compound SPA-S-753 shows promise in treating systemic candidosis in mice, demonstrating efficacy comparable to amphotericin B in prolonging survival and reducing fungal burden.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Systemic candidosis, a serious fungal infection, requires effective antifungal treatments.
- Amphotericin B is a standard treatment but has significant toxicity.
- Novel antifungal agents are needed to improve treatment outcomes.
Purpose of the Study:
- To evaluate the efficacy of the polyene partricin compound SPA-S-753 against Candida albicans systemic infection in a murine model.
- To compare the efficacy of SPA-S-753 with amphotericin B.
Main Methods:
- CD-1 mice were infected intravenously with Candida albicans.
- Mice were treated intravenously with SPA-S-753 or amphotericin B.
- Survival rates, fungal burdens in spleen and kidneys, and cure rates were assessed.
Main Results:
- Both SPA-S-753 and amphotericin B significantly prolonged survival compared to controls (P < 0.001).
- Both treatments significantly reduced Candida albicans burdens in the spleen and kidneys.
- SPA-S-753 demonstrated an efficacy between equivalent and <10-fold that of amphotericin B.
Conclusions:
- SPA-S-753 is a promising antifungal agent for systemic candidosis.
- Further studies are warranted to explore the therapeutic potential of SPA-S-753.
